Literature DB >> 2742681

The adult respiratory distress syndrome: first trials with surfactant replacement.

P S Richman1, R G Spragg, B Robertson, T A Merritt, T Curstedt.   

Abstract

Following diverse insults, patients may develop a high permeability lung oedema which results in tachypnoea, cyanosis, hypoxaemia, and pan-lobar infiltrates on the chest radiograph. Although a variety of interventional therapies have been evaluated, none has been found effective, and current treatments are entirely supportive. Recently, cellular and biochemical analyses of bronchoalveolar lavage fluid have disclosed abnormalities which suggest that acute inflammatory events and surfactant abnormalities are present in the lungs of patients with adult respiratory distress syndrome (ARDS). The similarities to abnormalities seen in neonates with respiratory distress syndrome are striking. Treatment of those infants with surfactant replacement has been of both short-term and long-term benefit. Therefore, it is rational to investigate the benefits which surfactant administration may have for patients with ARDS. We present an overview of ARDS, and our initial experience with surfactant replacement in three patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2742681

Source DB:  PubMed          Journal:  Eur Respir J Suppl        ISSN: 0904-1850


  12 in total

Review 1.  Ventilation and secretion of pulmonary surfactant.

Authors:  H Wirtz; M Schmidt
Journal:  Clin Investig       Date:  1992-01

Review 2.  Nonventilatory treatments for acute lung injury and ARDS.

Authors:  Carolyn S Calfee; Michael A Matthay
Journal:  Chest       Date:  2007-03       Impact factor: 9.410

3.  Surfactant therapy in patients with acute respiratory failure: report of two cases.

Authors:  H Rinka; Y Matsuo; T Shigemoto; T Yoshimura; M Kan; A Kaji; K Tsukioka; T Ukai
Journal:  J Anesth       Date:  1996-09       Impact factor: 2.078

4.  Transfusion-related acute lung injury treated with surfactant in a neonate.

Authors:  T J Wu; R J Teng; K I Tsou Yau
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

Review 5.  Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.

Authors:  Magda Cepkova; Michael A Matthay
Journal:  J Intensive Care Med       Date:  2006 May-Jun       Impact factor: 3.510

6.  Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters surface tension properties.

Authors:  N Gilliard; G P Heldt; J Loredo; H Gasser; H Redl; T A Merritt; R G Spragg
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

7.  In vivo evaluation of the inhibitory capacity of human plasma on exogenous surfactant function.

Authors:  B Lachmann; E P Eijking; K L So; D Gommers
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

8.  Dose-response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS).

Authors:  D Häfner; R Beume; U Kilian; G Krasznai; B Lachmann
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

9.  Severe reperfusion lung injury after double lung transplantation.

Authors:  Giorgio Della Rocca; Federico Pierconti; Maria Gabriella Costa; Cecilia Coccia; Livia Pompei; Monica Rocco; Federico Venuta; Paolo Pietropaoli
Journal:  Crit Care       Date:  2002-05-01       Impact factor: 9.097

Review 10.  The surfactant system of the adult lung: physiology and clinical perspectives.

Authors:  H Hamm; H Fabel; W Bartsch
Journal:  Clin Investig       Date:  1992-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.